Definition of hip fracture in elder population, risk factor, medical management.
and evaluating a journal club of article " Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults"
Evidence based management of osteoarthritis in primary care - Dr Jonathan Quickepcsciences
Dr Jonathan Quicke is an NIHR Academic Clinical Lecturer in Physiotherapy (Keele University). Dr Quicke presented at the 2017 Musculoskeletal Education Day, where he discussed how we can ensure that best practice can be implemented within general practice for patients suffering with osteoarthritis
Pearls about NSAIDs and their usage in the managaement of chronic pain, considering safety profile of both selective cox-2 or non selective cox-2 inhibitors
A comprehensive talk about rheumatic autoimmune diseases for patients and family or people interested in understanding SLE, Systremic sclerosis, dermatomyositis, rheumatoid arthritis. Some slides in Bahasa Indonesia.
A systematic approach as to how general physician assessing a patient with musculoskeletal pain with confident; with rheumatoid arthritis as a model. prepared with help of Dr. Perdana Aditya SpPD.KR from UNIBRAW Malang
A brief review about the role of vitamin D in health and disease. Most of the content in these slides were taken from another author with some editing to custom it for the purpose of general physician workshop scientific material. Some figures were our own data in our hospital
This is a brief introduction regarding selected rheumatic autoimmune disease for laymen. Some of these figures in the slides were cited from textbook and another authors elesewhere, and some of them were photos of patient taken with their permission
Penyakit Autoimun penting dikenali masyarakat awam karena gejalanya yang tersamar antar sesama autoimun, bahkan dengan penyakit lain yang bukan autoimun.
Sebuah edukasi pasien tentang lupus, meliputi berbagai aspek yang patut diketahui, agar pasien dan keluarganya tidak larut dalam fase denial dan bargaining yang berkepanjangan
Komordibitas pada pasien dengan gout di poliklinik reumatologi (edit)Rachmat Gunadi Wachjudi
Bagaimana komorbiditas pasien Gout di Indonesia ? Ini merupakan penelitian di satu rumah sakit di Bandung mengenai komorbiditas para penderita pirai alias gout
Beberapa kondisi klini yang harus membuat para praktisi klinis mulai mencurigai adanya penyakit autoimmune. Dijelaskan dengan beberapa contoh autoimmune dseases
Pengenalan artritis reumatoid berdasarkan gejala dan tanda klinis
Bisa dipakai sebagai rujukan bagi dokter umum yangh ingin mempelajari manifestasi klinis AR yang tidak klasik seperti di buku teks
an overview of Lupus for journalist
Lupus has a wide spectrum of manifestation. Some mild but in most cases it has a high impact of life and quality of life
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
2. Prevalence of Arthritis in US Adults*
■ 49.9 million (22.2%) with self-reported, physician-diagnosed arthritis†1
■ 21.1 million (9.4%) with arthritis and arthritis-attributable activity limitation1
■ Affects more women than men in every age group2
0
20
40
60
80
100
18–24 25–34 35–44 45–54 55–64 65–74 75–84 85+
Women Men
Age Group, years
* Data sources: 2007-2009 data from the National Health Interview Survey (NHIS). † Includes multiple forms of arthritis.
HCP=health care professional.
1. CDC. MMWR Morb Mortal Wkly Rep. 2010;59(39):1261-1265.
2. Graphic adapted from CDC. NHIS Arthritis Surveillance: Arthritis Prevalence in Women and Men.
www.cdc.gov/arthritis/data_statistics/national_nhis.htm. Accessed January 12, 2011.
3. CDC. MMWR Morb Mortal Wkly Rep. 2009;58(16):421-426.
4. Hootman JM, Helmick CG. Arthritis Rheum. 2006;54(1):226-229.
■ Arthritis and rheumatism → leading causes of disability in US3
■ By 2030, a projected 67 million in US will have HCP-diagnosed arthritis4
USAdults(%)
WithArthritis
3. Osteoarthritis: burden of disease
■ One in five people in the UK have arthritis1
■ Arthritis is the largest single cause of physical
disability in the UK2
■ Osteoarthritis (OA) is the most common form
of arthritis3
■ OA is associated with considerable burden of
disease – second only to cardiovascular
disease in causing severe disability3
4. OA in Primary Care
■ Most patients with OA are managed in Primary
Care4
■ Overall, muscloskeletal problems account for
one in ten (20%) of General Practice
consultations4
■ GPs have an opportunity to optimise patient
care in OA
5. Factors Implicated in the Development of OA
Cartilage breakdown
ObesityObesity
Anatomic
abnormalities
Anatomic
abnormalities
Microfractures
and bony
remodeling
Microfractures
and bony
remodeling
Loss of joint
stability
Loss of joint
stability
TraumaTrauma
AgingAging
Genetic and
metabolic
diseases
Genetic and
metabolic
diseases
InflammationInflammation
Immune
system
activity
Immune
system
activity
Compromised cartilage
Biophysical changes
• Collagen network fracture
• Proteoglycan unraveling
Biochemical changes
• Inhibitors reduced
• Proteolytic enzymes increased
Abnormal stresses Abnormal cartilage
Mandelbaum B et al. Orthopedics. 2005;28(2 suppl):s207-s214.
Adapted with permission from 2002 Medtronic Sofamor Danek, Basic Bone Biology.
6. EULAR Diagnostic Criteria for Knee OA (2010)
■ Based on review of studies from 1950-2008 and expert consensus
■ Focuses on clinical diagnosis: presence of three symptoms and
three signs correctly diagnoses 99% of cases
SymptomsSymptoms
1 Persistent knee pain √
2 Limited morning stiffness √
3 Reduced function √
SignsSigns
4 Joint crepitus √
5 Restricted movement √
6 Bony enlargement √
EULAR=European League Against Rheumatism.
Zhang W et al. Ann Rheum Dis. 2010;69(3):483-489.
7. ACR Diagnostic Criteria for Knee OA (1986)
■ Clarified and standardized definition of osteoarthritis
Joint symptoms and signs associated with defective integrity of
articular cartilage and changes in underlying joints at bone margin
■ Focuses on clinical examination of knee pain plus:
■ Sensitivity, 95%; specificity, 69%
Presence of 3 of the followingPresence of 3 of the following
1 Age >50 years √
2 Morning stiffness <30 minutes √
3 Joint crepitus on active motion √
4 Bony tenderness √
5 Bony enlargement √
6 No palpable warmth of synovium √
ACR=American College of Rheumatology.
Altman RD et al. Arthritis Rheum. 1986;29(8):1039-1049.
8. Key principles5
: EULAR guidelines
1. Treatment should be tailored to the patient
2. The relationship between the healthcare team
and the patient should be a two-way process
3. Using tools can help to assess the patient’s
pain and disability
4. Patient education has a significant impact on
pain management
5. Treatment should be a combination of
non-pharmacological and pharmacological
measures
9. Management options5:
EULAR guidelines
6. Non-pharmacological management strategies
should be incorporated
7. Paracetamol and NSAIDs should be used as
first-line pharmacotherapy
8. There is evidence to support the use of some
symptomatic slow-acting drugs for OA
(SYSADOA)
9. Corticosteroid intra-articular injections can be
useful in acute exacerbations
10. Consider surgery in patients unresponsive
to medical management
10. Key principle 1
Patient-tailored treatment
■ OA is a long-term, chronic condition and has a
considerable impact on quality of life5
■ Treatment should:
be tailored to the patient5
consider the individual patient’s needs in terms of
both functionality and of pain relief5
■ It is likely that each individual patient will have to
try a number of management options before
finding the combination which works best for
them5
11. Key principle 2
Doctor/patient relationship5
■ The relationship between the healthcare team
and the patient is key
■ The patient should be an active partner in disease
management
■ Involve the patient in treatment decisions and
listen to their concerns
■ The patient is an expert in their disease: they
know their pain better than anyone else and will
have developed strategies to deal with it
12. Key principle 3 Using tools
■ Tools can help to assess the patient’s pain and
disability
■ Tools include:
rating scales
questionnaires6
pain diagrams
■ Using tools before and after treatment is also
useful to determine whether treatment
is working
13. Pain drawings
Mark the area on your body
where you feel the described
sensations
Use the appropriate symbol
Mark the areas of radiation
Include all affected areas
Numbness = = = =
Pins and needles ° ° ° ° °
° Burning
xxxxxxxx
Stabbing / / / / / / /
15. Key principle 4 Patient education
■ Studies suggest that education is around 20% as
effective as NSAIDs, and can have a synergistic effect
with other treatments8
■ Patient information and self-management strategies can
empower patients to take control of their arthritis
■ Effective education techniques include:
individual education packs
regular telephone calls
group education
patient coping skills
spouse assisted coping skills training5
16. Key principle 5 Management options
■ Treatment should be a combination of
non-pharmacological and
pharmacological measures5
■ Indirect evidence suggests non-
pharmacological treatments offer additional
benefits over and above treatment with
NSAIDs and analgesics5
17. Goals of OA Management:
OARSI Recommendations
Reduce
joint pain and
stiffness
Reduce
physical
disability
Improve
HRQoL
Educate
patients
Limit
progression of
joint damage
Knee and Hip OA:
Goals of
Treatment
HRQoL=health-related quality of life; OARSI=Osteoarthritis Research Society International.
Zhang W et al. Osteoarthritis Cartilage. 2008;16(2):137-162.
Maintain and
improve joint
mobility
18. Integrated Approach to Treating Patients With OA
NonpharmacologicNonpharmacologic PharmacologicPharmacologic
■ Patient education
■ Phone contact (promote self-care)
■ Referral to physical therapist
■ Aerobic, strengthening, and/or water-
based exercise
■ Weight reduction
■ Walking aids, knee braces
■ Proper footwear, insoles
■ Thermal modalities
■ TENS
■ Acupuncture
■ APAP
■ Oral NSAIDs
■ Topical NSAIDs and capsaicin
■ Corticosteroid injections
■ Hyaluronate injections
■ Glucosamine, chondroitin sulphate,
and/or diacerein
■ Weak opioids and narcotic analgesics
for refractory pain*
SurgicalSurgical
■ Total joint replacement
■ Unicompartmental knee replacement
■ Osteotomy and other joint preserving
surgical procedures
■ Lavage/debridement in knee OA†
■ Joint fusion after failure of joint
replacement
* Pain resistant to ordinary treatment. † Controversial.
TENS=transcutaneous electrical nerve stimulation.
Zhang W et al. Osteoarthritis Cartilage. 2008;16(2):137-162.
19. Management option 6
Non-pharmacological management
■ Life-style modification has an important
role in management5,9
■ For example5
:
weight loss
exercise
– quadriceps strengthening
– range of movement
– general fitness
– hydrotherapy
assistive devices (canes and frames)
appropriate footwear, insoles
20. Management option 6
Non-pharmacological management
■ Little formal evidence to support complementary
therapies, but some patients derive considerable
benefit
■ Examples of complementary therapies include:
Acupuncture
Alexander technique
Aromatherapy
Chiropractice
Hydrotherapy Massage
Osteopathy
Reflexology
Tai chi
21. Management option 6
Non-pharmacological management
■ Self-management strategies can improve
patients’ ability to manage their pain and
disability of OA5
■ Access to patient organisations and
support groups which provide help and
advice
22. Management option 7
Analgesia and NSAIDs
■ Use paracetamol as first-line therapy5
■ It is likely that the majority of patients will have already tried
over-the-counter paracetamol5
■ In those patients with a poor response to paracetamol,
NSAIDs should be considered5
■ NICE guidance recommends that COX-2 selective
inhibitors should be considered only in patients who may
be at high risk of developing serious gastro-intestinal (GI)
adverse events10
■ The European Medicines Agency advised doctors that
Cox-2 selective inhibitors should only be prescribed to
people with arthritis at ‘the lowest effective dose for the
shortest possible duration’. (EMEA 27 June 2005)
23. Management option 7 (1)
COX-2 selective inhibitors
■Consider in patients who may be at high risk of
developing serious GI adverse events, and in
whom an NSAID is clearly indicated10
See over for updated Cox-2 prescribing guidelines
24. Management option 7 (1a)
COX-2 selective inhibitors
■High-risk patients include, those:
aged 65 years and over,
with a previous clinical history of gastroduodenal
ulcer, GI bleeding or gastroduodenal perforation.
The use of even a COX-2 selective agent should be
considered especially carefully in this situation,
taking concomitant medication(s) that are known to
increase the likelihood of upper GI adverse events
(eg corticosteroids, anti-coagulants)
24
Please see Full Prescribing Information available at this presentation.
25. Management option 7 (2)
COX-2 selective inhibitors
June 2005 – The European Medicines Agency reviewed
Cox-2 selective inhibitors, they concluded that:
– the risks of potential fatal skin reactions with Valdecoxib (Bextra)
outweighed the benefits and suspended Valdecoxib for a year,
pending a review. Pfizer voluntarily withdrew Valdecoxib
– other Cox-2 selective inhibitors (Celecoxib, Etoricoxib,
Lumiracoxib, Parecoxib) will have stronger guidelines for
prescription:
– Cox-2s should not be prescribed to people with ischaemic heart
disease, cerebrovascular disease or peripheral arterial disease
– caution when prescribing Cox-2s to people with heart disease,
hypertension, hyperlipidaemia (cholesterol), diabetes and smokers
– doctors are advised to prescribe the lowest effective Cox-2 dose
for the shortest possible duration
27. McKenna F et al. Scand J Rheumatol 2001;30:11–18.
VAS=visual analogue scale.
LessPain
Patient’s Assessment of Pain (VAS): Mean change at
week 6
MeanChange(mm)
*p=0.001 vs. placebo
placebo
(n=200)
celecoxib
100 mg BID
(n=199)
diclofenac
50 mg TID
(n=199)
CELECOXIBvs. diclofenac:
6-week Knee OA Trial
McKenna et al. 2001: Patient’s Assessment of Pain
28. McKenna F et al. Scand J Rheumatol. 2001;30:11-18.
American Pain Society (APS) Pain Measure:
Worst Pain in the Past 24 Hours
MeanChangeinScore
p=0.05, active treatment vs.
placebo (days 1-7).
-4.0
-3.5
-3.0
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
Baseline Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
placebo (n=200)
celecoxib 100 mg BID (n=199)
diclofenac 50 mg TID (n=199)
LessPain
CELECOXIBvs. diclofenac:
6-week Knee OA Trial
McKenna et al. 2001: American Pain Society – Pain
Measure
32. Boxed Warning for All Prescription NSAIDs
Cardiovascular Risk
NSAIDs may cause an increased risk of serious cardiovascular thrombotic
events, myocardial infarction, and stroke, which can be fatal. This risk may
increase with duration of use. Patients with cardiovascular disease or risk
factors for cardiovascular disease may be at greater risk.
[Product] is contraindicated for the treatment of perioperative pain in the
setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Risk
NSAIDs, including [product], cause an increased risk of serious
gastrointestinal adverse events including bleeding, ulceration, and
perforation of the stomach or intestines, which can be fatal. These events
can occur at any time during use and without warning symptoms. Elderly
patients are at greater risk for serious gastrointestinal (GI) events.
Cardiovascular Risk
NSAIDs may cause an increased risk of serious cardiovascular thrombotic
events, myocardial infarction, and stroke, which can be fatal. This risk may
increase with duration of use. Patients with cardiovascular disease or risk
factors for cardiovascular disease may be at greater risk.
[Product] is contraindicated for the treatment of perioperative pain in the
setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Risk
NSAIDs, including [product], cause an increased risk of serious
gastrointestinal adverse events including bleeding, ulceration, and
perforation of the stomach or intestines, which can be fatal. These events
can occur at any time during use and without warning symptoms. Elderly
patients are at greater risk for serious gastrointestinal (GI) events.
33. 09/25/09
APTC Composite End Point (Adjudicated):
Celecoxib vs ns-NSAIDs
Meta-analysis of 25 RCTs
White et al. Am J Cardiol. 2007.
RelativeRisk(CI)ofSerious
CVAdverseEvents
ns-NSAIDs
(n=13,990)
Celecoxib 200-800 mg daily
(n=19,773)
0.90
(95% CI: 0.60-1.33)
2.0
1.5
0.5
0
1.0
1.0
49 events
54 events
P=.59 (NS)
34. CELECOXIB vs. naproxen & etoricoxib:
CV Safety Profile
Schwartz et al. 2007: Blood pressure change
Compared to naproxen and etoricoxib, celecoxib only shows significant change compared to placebo.
Meanwhile etoricoxib shows significant increase compared to placebo, baseline, and celecoxib and
naproxen.
+ Significantly different from placebo (P ≤ .05)
* Significantly different from baseline (P ≤ .05), placebo (P ≤ .05), and naproxen and celecoxib (P < .03)
Schwartz JI et al. J Clin Pharmacol 2007;47:1521-31.
+
+
*
+ +
*
Average blood pressure over a 24-hour period between days 1-14
2.4
3.6
7.7
0
1
2
3
4
5
6
7
8
9
Systolicbloodpressure,mmHg
celecoxib 200 mg BID (n=21) naproxen 500 mg BID (n=21) etoricoxib 90 mg OD (n=21)
35. Moore RA et al. BMC Musculoskelet Disord 2007;8:73.
celecoxib – Annually, per 1,000 patients, there were:
•12 fewer upper GI complications
•2 fewer fatal/non-fatal heart attacks or strokes
celecoxib
etoricoxib
lumiracoxib
all coxibs
Event rate difference (coxib-NSAID per 1000 per year)
Favours coxib Favours ns-NSAID
GI bleed difference
CV event dfifference
Coxibs vs. ns-NSAIDs: GI and CV Benefit/Risk Profile
Moore et al. 2007: GI and CV Event Rates
37. Incidence of patients with treatment-related
CV, renal, and hepatic AEs
1.7
1.1
4.1
5.2
0
1
2
3
4
5
6
CV / renal AE Hepatic AE
%Patients
celecoxib 200 mg OD diclofenac 50 mg BID
CELECOXIB vs. diclofenac
Dahlberg et al. 2009: CV / renal & hepatic AEs
One-year, randomized, multicentre, double-blind, parallel-group study to assess the AE-related discontinuation rate with
celecoxib and diclofenac in elderly patients with OA.
No p-values reported for related/not-related-to-treatment incidence. Significantly fewer patients in the celecoxib group than
the diclofenac group experienced cardiovascular/renal AEs (70/458 vs. 95/458, p=0.039) or hepatic AEs (10/458 vs. 39/458,
p<0.0001).
Dahlberg LE et al. Scand J Rheumatol 2009;38:133-143.
38. Prevalence of hepatic events
0.24
0.97
0.59
0.5
0.37
0.31
0.21
0
0.2
0.4
0.6
0.8
1
1.2
%hepaticevents
celecoxib
diclofenac
ketoprofen
meloxicam
etodolac
piroxicam
ibuprofen
CELECOXIB vs ns-NSAIDs:Hepatic Safety Profile
Sanchez-Matienzo et al. 2006: Prevalence of hepatic events
A case/noncase analysis of spontaneous reports was conducted to compare the hepatic safety profile of COXIBs and ns-
NSAIDs.
Sanchez-Matienzo D et al. Clin Ther 2006;28:1123-1132.
39.
40. Management option 8
Symptomatic slow-acting drugs of OA
■ Symptomatic slow-acting drugs of OA
(SYSADOA)
glucosamine
chondroitin
hyaluronic acid
diacerein
■ Supported by increasing evidence, although
further research is still required5,8,11,12
■ Given that these agents appear to be well
tolerated and do show some benefit their use
should be considered13
41. Management option 9
Corticosteroid injections
■ Corticosteroid intra-articular injections may
be used in the management of patients
with OA of the knee5
■ Provide superior short-term efficacy (2-4
weeks) versus placebo8
■ Recommended for acute exacerbations5
42. Management option 10
Surgery
■ Refer for orthopaedic evaluation if patient is
disabled by OA or in pain unrelieved by
medical management5,9
■ Joint replacement can be very effective5
■ Newer techniques such as metal-on-metal
resurfacing are less invasive15
■ Patients should be made aware of the risks
and benefits of surgery
43. Other useful resources
Arthritis Research Campaign
http://www.arc.org.uk
Primary Care Rheumatology Society
http://www.pcrsociety.com
British Society for Rheumatology
http://www.rheumatology.org.uk
The European League Against Rheumatism
http://www.eular.org
National Library for Health – Musculoskeletal Library
http://libraries.nelh.nhs.uk/musculoskeletal
Primary Care Question & Answer Service
http://www.clinicalanswers.nhs.uk/index.cfm
44. References 1-9
1. Arthritis Care. 1 in 5 – The prevalence and impact of arthritis in the UK (Research report).
February 2002.
2. Disability Care and Mobility Quarterly Statistical Enquiry - Disability Living Allowance,
Attendance Allowance and Invalid Care Allowance. Dept of Work and Pensions 2002.
3. Watson M. Management of patients with osteoarthritis. Pharm J 1997;259:296-297.
4. Royal College of General Practitioners OPCS Department of Health and Social Security.
Morbidity statistics from General Practice. Fourth National Survey 1991-1992. HMSO,
1996.
5. Jordan KM, Arden NK, Doherty M et al. EULAR recommendations 2003: an evidence
based approach to the management of knee osteoarthritis: Report of a task force of the
Standing Committee for International Clinical Studies Including Therapeutic Trials
(ESCISIT). Ann Rheum Dis 2003;62:1145-1155.
6. Dawson J, Fitzpatrick R, Murray D et al. Questionnaire on the perceptions of patients
about total knee replacement. J Bone Joint Surg (Br) 1998;80:63-69.
7. Creamer P, Lethbridge-Cejku M, Hochberg MC. Factors associated with functional
impairment in symptomatic knee osteoarthritis. Rheumatology 2000;39:490-496.
8. Walker-Bone K, Javaid K, Arden N et al. Regular review: Medical management of
osteoarthritis. BMJ 2000;321:936-940.
9. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000
update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines.
Arthritis Rheum 2000;43(9):1905-1915.
45. References 10-15
10. Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib,
rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. NICE
Technology Appraisal Guidance 27, July 2001.
11. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The
role of glucosamine, chondroitin sulfate and collagen hydrolysate. Rheum Clin N Am
1999;25:379-395
12. Is glucosamine worth taking for osteoarthritis. Drug & Ther Bull 2002;40:81-83.
13. Chard J, Dieppe P. Glucosamine for osteoarthritis: Magic, hype, or confusion? It's
probably safe-but there's no good evidence that it works. BMJ 2001;322(7300):1439-
1440.
14. Guidance on the selection of prostheses for primary total hip replacement. NICE
Technology Appraisal Guidance 2, April 2000.
15. Guidance on the use of metal on metal hip resurfacing arthroplasty. NICE
Technology Appraisal Guidance 44, June 2002.
46. 46
Please see Full Prescribing Information available at this presentation.
THANK YOU
Editor's Notes
Data from the 2007-2009 National Health Interview Survey reveal high rates of self-reported, doctor-diagnosed arthritis and limitations due to arthritis.1 In addition, in every adult age group, women are more likely to be affected by arthritis than men.2
Arthritis and rheumatism are the leading causes of disability in the United States,3 and it is estimated that by 2030, 67 million Americans will have health care practitioner-diagnosed arthritis.4
References:
Centers for Disease Control and Prevention. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation — United States, 2007–2009. MMWR Morb Mortal Wkly Rep. 2010;59(39):1261-1265.
Centers for Disease Control and Prevention. NHIS Arthritis Surveillance: Arthritis Prevalence in Women and Men. www.cdc.gov/arthritis/data_statistics/national_nhis.htm. Accessed January 12, 2011.
Centers for Disease Control and Prevention. Prevalence and most common causes of disability among adults—United States, 2005. MMWR Morb Mortal Wkly Rep. 2009;58(16):421-426.
Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54(1):226-229.
It has been estimated that one in five of the population - over nine million people - in the UK have arthritis1. Osteoarthritis (OA) is the most common form3 and is associated with considerable morbidity. It is second only to cardiovascular disease in causing severe morbidity3, in fact, arthritis is the largest single cause of physical disability in the UK2.
By far the majority of patients with OA are managed in Primary Care – with musclo-skeletal problems accounting for one in ten (10%) of General Practice consultations4. However, management of OA in Primary Care is limited by resources, especially the GP’s available time – the average GP consultation time is 7-8 minutes. Bearing in mind that patients are likely to present more than one problem per consultation – time spent specifically dealing with OA becomes even more limited.
Despite the high prevalence and the burden of disease, musculoskeletal medicine is not a priority area to most practices. This is further compounded by a lack of formal training in musculoskeletal medicine and the absence of national targets (National Service Framework and so forth).
Research from Arthritis Care suggests that around one-quarter of patients with arthritis are dissatisfied with the treatment that they receive from their GP, 82% feel that their GP does not have a good understanding of their condition and 85% feel that arthritis is not given a high enough priority1. It is hoped that this educational support programme will aid in building GP-patient relationships and improve overall quality of care. Early diagnosis of OA and appropriate management can reduce disability through treatment, education, and alterations in lifestyle and activities.
This slide provides an overview of the factors that can contribute to the development of OA.
These factors can be divided into two groups: those placing abnormal stress on the cartilage, such as obesity and anatomic abnormalities, and those contributing to abnormalities of the cartilage, such as aging and genetic diseases.
All of these factors can contribute to compromised cartilage and ultimately result in cartilage breakdown.
Reference:
Mandelbaum B, Waddell D. Etiology and pathophysiology of osteoarthritis. Orthopedics. 2005;28(2 suppl):s207-s214.
In 2010, the European League Against Rheumatism (EULAR) provided six criteria—three symptoms and three signs—that could be used to correctly diagnose OA of the knee in 99% of cases, when all six criteria are present.
The three symptoms are:
Persistent knee pain
Limited morning stiffness
Reduced function
The three signs are:
Joint crepitus
Restricted movement
Bony enlargement
Reference:
Zhang W, Doherty M, Peat G, et al. EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis. 2010;69(3):483-489.
In 1986 the American Rheumatism Association—now the American College of Rheumatology (ACR)—developed criteria to diagnose OA on the basis of knee pain and three of the following six criteria:
Age older than 50 years
Less than 30 minutes of morning stiffness
Joint crepitus
Bony tenderness
Bony enlargement
Absence of palpable warmth
The sensitivity and specificity of these criteria were 95% and 69%, respectively.
Reference:
Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29(8):1039-1049.
These five key principles are based around the EULAR guidelines5 and practical GP experience:
Treatment should be tailored to the patient
The relationship between the healthcare team and the patient should be a two-way process
Using tools can help to assess the patient’s pain and disability
Patient education has a significant impact on pain management
Treatment should be a combination of non-pharmacological and pharmacological measures.
As we have already discussed, treatment should be a combination of non-pharmacological and pharmacological measures5:
Non-pharmacological management strategies – life-style modification, education, self-management – should be included in management options
Paracetamol and NSAIDs should be used as first-line pharmacotherapy. COX-2 selective inhibitors should be considered only in patients at high risk of gastro-intestinal events
There is evidence to support the use of some symptomatic slow-acting drugs for OA (SYSADOA) e.g. glucosamine, chondroitin and hyaluronic acid
Corticosteroid intra-articular injections can be useful in acute exacerbations
Consider surgery in patients unresponsive to medical management.
OA is a long-term, chronic condition and has a considerable impact on quality of life – influencing many aspects of the patient’s health – both emotional and physical. Treatment should be tailored to the patient – and should consider the individual patient’s needs in terms of both functionality and of pain relief5.
It is likely that each individual patient will sample a number of management options before finding the combination which works best for them. This is clarified in the 2003 EULAR guidelines which state that ‘There is no single right or wrong approach, and each health professional must decide with each patient the most appropriate management plan at a particular time and for that location’ 5.
Patients should be actively involved with treatment decisions and their concerns heard. Listen to the patient: remember that they know their pain better than anyone else and will have developed strategies to deal with it. It is essential that the patient is an active partner in their disease management and is kept fully informed of the diagnosis and treatment options. Giving patients the confidence and information to take responsibility for their health, can help patients to manage their OA more effectively and improve quality of life5.
Tools such as rating scales/questionnaires/pain diagrams can help to assess the patient’s pain and disability6. Using such tools before and after treatment is also useful to determine whether treatment is working, as radiological changes do not always correlate with disability or function7.
Studies suggest that education is around 20% as effective as NSAIDs, and can have a synergistic effect with other treatments8. Patient information and self-management strategies can empower patients to take control of their arthritis. Arthritis Care run a range of self-management courses including Challenging Arthritis and the Positive Future workshops aimed at younger people.
The optimal management of OA requires a combination of non-pharmacological and pharmacological treatment5. Non-pharmacological management strategies include lifestyle modifications, complementary therapies and self-management strategies and are covered in the next three slides.
Consensus guidelines from the Osteoarthritis Research Society International (OARSI) indicate six key goals for the treatment of knee and hip OA.
Four of these goals relate to the patient’s physical state:
Reduce joint pain and stiffness
Maintain and improve joint mobility
Reduce physical disability
Limit progression of joint damage
The other two key goals are to educate the patient about OA and its management, and to improve patient’s health-related quality of life.
Reference:
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-62.
The Osteoarthritis Research Society International (OARSI) consensus guidelines describe an integrated approach to treating patients with OA, including nonpharmacologic, pharmacologic, and surgical interventions.
Nonpharmacologic aspects of treatment include such interventions as patient education, exercise, weight reduction, and the nondrug therapies transcutaneous electrical nerve stimulation (TENS) and acupuncture.
Listed among the pharmacologic treatments are acetaminophen, selective and nonselective NSAIDs, steroid injections, glucosamine and chondroitin, and for some patients, weak opioids and narcotic analgesics.
Surgical interventions listed in the guidelines include total joint replacement, joint fusion in cases of replacement failure, unicompartmental knee replacement, osteotomy, and lavage and debridement in knee OA, although this last approach is controversial.
Reference:
Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-62.
Lifestyle modifications which include weight loss, exercise (quadriceps strengthening, range of movement and general fitness, hydrotherapy), appliances (canes, frames and knee bracing) and appropriate footwear5,9 all have an important role in management.
Complementary therapies include acupuncture, Alexander technique, aromatherapy, chiropractic, hydrotherapy, massage, osteopathy, reflexology and Tai Chi. Although, there is little formal evidence to support their use some patients derive considerable benefit from these treatments.
Self-management strategies can substantially improve patients’ ability to manage the pain and disability associated with OA5. Access to patient organisations and support groups for help and advice can be extremely helpful (e.g. Arthritis Care helplines: Freephone helpline: 0808 800 4050 Monday-Friday, 12 noon-4 pm National rate helpline: 020 7380 6555 Monday-Friday, 10 am-4 pm)
Although EULAR guidelines recommend paracetamol or NSAIDs, paracetamol is generally recommended as first-line pharmacotherapy in the majority of patients with OA. It is likely that most patients will have already tried over-the-counter medicines including paracetamol5. Therefore when considering treatment options ask the patient about any over-the-counter medications (including oral or topical analgesia) and any alternative medicines which they are taking. Only in those patients with a poor response to paracetamol, should NSAIDs be considered5. The National Institute of Clinical Excellence (NICE) recommends that COX-2 selective inhibitors should be considered only in patients who may be at ‘high risk’ of developing serious gastro-intestinal (GI) adverse events and when clearly indicators10.
NICE recommends that COX-2 selective inhibitors should be considered only in patients who may be at ‘high risk’ of developing serious GI adverse events, and in whom an NSAID is clearly indicated10. High risk patients include, those:
aged 65 years and over,
with a previous clinical history of gastroduodenal ulcer, GI bleeding or gastroduodenal perforation. The use of even a COX-2 selective agent should be considered especially carefully in this situation,
taking concomitant medication(s) that are known to increase the likelihood of upper GI adverse events (e.g. corticosteroids, anti-coagulants),
with serious co-morbidity, such as cardiovascular disease, renal or hepatic impairment, diabetes and hypertension
who have a requirement for the prolonged use of maximum recommended doses of standard NSAIDs.
NICE recommends that COX-2 selective inhibitors should be considered only in patients who may be at ‘high risk’ of developing serious GI adverse events, and in whom an NSAID is clearly indicated10. High risk patients include, those:
aged 65 years and over,
with a previous clinical history of gastroduodenal ulcer, GI bleeding or gastroduodenal perforation. The use of even a COX-2 selective agent should be considered especially carefully in this situation,
taking concomitant medication(s) that are known to increase the likelihood of upper GI adverse events (e.g. corticosteroids, anti-coagulants),
with serious co-morbidity, such as cardiovascular disease, renal or hepatic impairment, diabetes and hypertension
who have a requirement for the prolonged use of maximum recommended doses of standard NSAIDs.
Key point: Celecoxib relieves OA pain of the knee as effectively as diclofenac.
Background: All efficacy outcomes were significantly superior with celecoxib compared with placebo at both week 2 and week 6. In the primary efficacy analysis of patient’s assessment of pain by VAS, there was no statistically significant difference between celecoxib and diclofenac.
Reference:
McKenna F et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001;30:11-18.
Key point: Celecoxib decreased APS pain measure of worst pain in the past 24 hours as effectively as diclofenac.
Background: Celecoxib reduced the amount of acute pain experienced by patients with knee OA compared with placebo within the first 24 hours of therapy. The American Pain Society (APS) pain measures were significantly improved with celecoxib compared with placebo on day 1, and this response was maintained throughout the 7-day evaluation period (p&lt;0.01). By day 7, 7% of patients taking placebo, 17% of those treated with celecoxib, and 15% of those treated with diclofenac reported no pain (p&lt;0.01, active treatment vs. placebo). Pain response was similar between celecoxib and diclofenac groups.
Reference:
McKenna F et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee: a placebo-controlled, randomised, double-blind comparison. Scand J Rheumatol 2001;30:11-18.
Patients with risk factors for cardiovascular disease (i.e., prior history of a cardiovascular event, diabetes, hypertension, hyperlipidemia, and obesity) oI en receive prophylactic aspirin. - ey may bene5 t from the substitution of a less cardiotoxic NSAID instead of a COX-2 inhibitor. Naproxen may be the agent of choice as it may have some cardioprotective properties (76,98,108,109,112) . In addition, these patients should receive a PPI or misoprostol because the combination of naproxen and low-dose aspirin markedly increases the risk of GI bleeding. Patients at very high GI risk who also have increased CV risk should not be treated with NSAIDs or coxibs and another form of treatment should be considered.
Reference:
Lanza FL et al. Am J Gastroenterol 2009;104:728-738
In April 2005, the FDA issued request letters to manufacturers of all NSAIDs, asking that they make labeling changes to their products.1 These letters included recommended labeling for both prescription and over-the-counter NSAIDs and a medication guide for the entire class of prescription products. All manufacturers of marketed prescription NSAIDs, including Celebrex (celecoxib), were asked to revise the labeling (package insert) for their products to include a boxed warning (shown), which highlights the potential for an increased risk of cardiovascular (CV) events.2-4
Manufacturers of over-the-counter NSAIDs were also asked to revise their labeling to provide more specific information about the potential CV risks of their individual products.
References:
FDA. COX-2 selective (includes Bextra, Celebrex, and Vioxx) and non-selective non-steroidal anti-inflammatory drugs (NSAIDs). April 7, 2005. www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm103420.htm. Accessed January 12, 2011.
Celebrex [package insert]. New York, NY: Pfizer Inc.; June 2009.
EC-Naprosyn/Naprosyn/Anaprox/Anaprox DS [package insert]. Nutley, NJ: Roche Pharmaceuticals; July 2008.
Voltaren-XR [package insert]. East Hanover, NJ: Novartis; March 2009.
This slide represents results of the analysis of 25 completed clinical trials that compared celecoxib with nonselective NSAIDs. A total of 19,773 patients treated with a total daily celecoxib dose of 200-800 mg were compared with 13,990 patients treated with nonselective NSAIDs (all nonselective NSAIDs combined, any dose).1
There were no significant differences in adjudicated APTC event rates for celecoxib compared with nonselective NSAIDs (RR 0.90; 95% CI: 0.60-1.33), as shown in the slide, nor for unadjudicated event rates (RR 0.86; 95% CI: 0.59-1.26) (not shown).1,2
The basis of evaluating relative risk was event rate per 100 patient years.1
References
1. White WB, West CR, Borer JS, et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am J Cardiol. 2007;99:91-98.
2. FDA February 16-18, 2005 Joint Meeting with the Drug Safety and Risk Management Advisory Committee. Available at: http://www.fda.gov/ohrms/dockets/ac/cder05.html#ArthritisDrugs. Accessed January 11, 2007.
Key point: Celecoxib offers a favourable benefit/risk profile vs. ns-NSAIDs and other coxibs with 12 fewer upper GI complications and 2 fewer fatal/non-fatal heart attacks or strokes per 1,000 patients.
Background: This study calculated the absolute risk GI and CV events. Studies with large amounts of information were included in the calculation of annualized rates for clearly defined gastrointestinal (complicated upper gastrointestinal perforations, ulcers, or bleeds, but not symptomatic or endoscopic ulcers) and serious cardiovascular outcomes (antiplatelet trial collaborators - APTC - outcome of fatal or nonfatal myocardial infarction or stroke, or vascular death). Meta-analyses and large randomized trials specifically analyzing serious gastrointestinal bleeding or cardiovascular events occurring with 5 different coxibs had appropriate data. In total there were 439 complicated upper gastrointestinal events in 49,006 patient-years of exposure and 948 serious cardiovascular events in 99,400 patient-years of exposure. Complicated GI events occurred less frequently with coxibs than ns-NSAIDs; serious CV events occurred at approximately equal rates. For each coxib (celecoxib, lumiracoxib, rofecoxib, valdecoxib and etoricoxib), the reduction in complicated upper GI events was numerically greater than any increase in APTC events. In the overall comparison, for every 1,000 patients treated for a year with a coxib rather than ns-NSAID, there would be 8 fewer complicated upper GI events, but one more fatal or nonfatal heart attack or stroke. However, varying results were obtained for different coxib-ns-NSAID comparisons. For example, for every 1,000 patients treated for a year with celecoxib rather than a ns-NSAID, there would be 12 fewer upper GI complications, and 2 fewer fatal or nonfatal heart attacks or strokes. For rofecoxib (no longer on the market), there would be 6 fewer upper GI complications, but 3 more fatal or nonfatal heart attacks or strokes. For lumiracoxib, there would be 8 fewer upper GI complications, but 1 more fatal or nonfatal heart attack or stroke.
Reference:
Moore RA et al. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord 2007;8:73.
There is growing evidence to support SYSADOA and recent data suggest that glucosamine sulphate could be used as a structure modifying agent in knee OA5, although further research is still required5,8,11,12. However, given that these agents appear to be well tolerated and do show some benefit their use should be considered13.
Corticosteroid intra-articular injections may be used in the management of patients with OA of the knee5. They provide superior short-term efficacy (2-4 weeks) versus placebo8. They are recommended for acute exacerbations, but have minimal medium to long-term effects5.
Patients with radiographic evidence of OA and severe symptomatic pain which is not relieved by medical management should be referred to an orthopaedic surgeon for evaluation5,9. Joint replacement can transform lives of patients with severe OA5. NICE guidance recommends that replacement hip joints should last for 10 years or more (10% revision rate at 10 years)14.
A newer technique - metal on metal resurfacing - replaces damaged surfaces in the joint with metal surfaces. Less bone is removed than when fitting a conventional joint replacement. Resurfacing is indicated in younger patients, aged under 65 years, who are likely to outlive the life of a total hip replacement or those who take part in activities which are likely to shorten the life of a total hip replacement15.
It is important that patients are made aware of the risks and benefits of any surgery – and in particular that less is known about resurfacing than conventional joint replacement.
The Arthritis Research Campaign aims to advance the understanding, prevention and treatment of arthritis and related conditions. The website provides information to people affected by arthritis and to the general public.
The Primary Care Rheumatology Society aims to improve education in rheumatology in general practice, to set up relevant research topics, to increase communication between hospital rheumatologists and other relevant health professionals, with the ultimate aim of improving care for patients with rheumatic disease.
The British Society for Rheumatology (BSR) is the UK professional organisation for people working in rheumatology and related fields. The principal objective of the BSR is to advance the science and practice of rheumatology and to promote study and research through scientific meetings and educational courses. They have an extensive links page on their website.
European League Against Rheumatism (EULAR) aims to promote, stimulate and support the research, prevention, treatment and rehabilitation of rheumatic diseases. The EULAR web site provides up to date information in the field of rheumatology to Allied Health Professionals, Social Leagues and Patient Organisations
Patient UK provides over 500 leaflets on health and disease together with details of over 2,000 self-help/patient support groups and similar organisations. It also provides a directory of useful health-focused UK websites.